- Policy
- SR version of gabapentin enters Korean market
- by Lee, Tak-Sun Nov 2, 2023 05:35am
- The first sustained-release formulation of gabapentin, which is used for nerve pain, has been introduced to Korea. The drug is Alvogen Korea’s Gralise SR Tab. The drug will be reimbursed from November and is expected to improve the convenience of intake for patients. According to industry sources on the 1st, Gralise SR Tab 600mg wil
- Policy
- There were more than 20 doses of Dapagliflozin 5mg
- by Lee, Tak-Sun Nov 2, 2023 05:35am
- Even though there are 21 SGLT-2 series Dapagliflozin propanediol hydrate 5mg products listed for reimbursement, the stepped drug price was not applied to the newly listed items in November. Why? This is because all 21 products were viewed as first-time registered products. According to the industry on the 1st, Nexpharm Korea's 'Floga 5mg'
- Policy
- Complete deletion of Ranitidine from the list of benefits
- by Lee, Tak-Sun Nov 1, 2023 05:40am
- Most ranitidine products, which were suspended due to adulteration in September 2019, will be removed from the reimbursement list as of November. This is because there has been no production performance over the past three years or no insurance benefit claims over the past two years. There are only three Ranitidine products remaining on the
- Policy
- Hanmi recieves 1st approval for aspirin+rabeprazole combo
- by Lee, Hye-Kyung Nov 1, 2023 05:40am
- With the development of aspirin and rabeprazole sodium combinations in active progress, Hanmi Pharmaceutical successfully obtained the first marketing authorization for its combination drug. The Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's Raspirin Cap. 100/5mg (aspirin/rabeprazole) on the 30th. The combination of a
- Policy
- HIRA ‘Will advance CDDC result disclosure within the year'
- by Lee, Jeong-Hwan Oct 31, 2023 05:35am
- The Health Insurance Review and Assessment Service announced that it will pursue systemic advancement within the year so people can gain access to details such as the reasons for the evaluations made by the Cancer Disease Review Committee. HIRA also revealed plans to review the scope, method, and timing of disclosure of the details of the
- Policy
- Roche Lunsumio, domestic approval imminent
- by Lee, Hye-Kyung Oct 31, 2023 05:35am
- According to the pharmaceutical industry on the 30th, the Ministry of Food and Drug Safety completed the safety and effectiveness review of Lunsumio. Completing this review means that the product approval process will soon begin. Lunsumio was designated as a GIFT item as the urgency of its introduction to expand patient treatment opportunitie
- Policy
- Dupixent receives the green light for reimb extensions
- by Lee, Tak-Sun Oct 30, 2023 05:30am
- The insurance authorities showed a positive stance on expanding coverage of Dupixent (dupilumab, Sanofi), which is available for patients with severe atopic dermatitis from 6 years of age, to critically ill infants and toddlers from 6 months to 5 years of age. Depending on the cost-effective review results, the reimbursement process may ga
- Policy
- NA criticizes HIRA's low prior approval of specific drug
- by Lee, Tak-Sun Oct 30, 2023 05:29am
- In response to the criticism that the prior review approval rate of certain drugs is low, the Health Insurance Review and Assessment Service said that the low rate is due to a lack of understanding of the reimbursement standards and that it will maintain the current standards. The response was made regarding the low approval rate of Sol
- Policy
- New dug price reeval standards will be set within the year
- by Lee, Jeong-Hwan Oct 27, 2023 05:33am
- The Health Insurance Review and Assessment Service said, “We will prepare a final plan within this year” to an inquiry on the progress made on the reevaluation of off-patent drugs through a comparison of overseas drug prices. In particular, based on the established reevaluation standards, HIRA also expressed their intention to sequentia
- Policy
- Galvusmet generics released in all dosage forms in KOR
- by Lee, Tak-Sun Oct 27, 2023 05:33am
- The second round of competitions is now on with the entry of Galvusmet generics. If the first round was held between generics before and after Galvusmet’s substance patent expiry, the second round this time expected this time is set to start with the release of Galvusmet generics that come in all dosage forms. According to the indus
